Goldline Pharmaceutical's initial public offering (IPO), which opened on May 12 and closes on May 14, has attracted substantial investor interest, achieving a subscription rate of 211.41x by the third day. The IPO price band is set at ₹41 to ₹43 per equity share, and the minimum bid is for 3,000 shares. The company's product portfolio includes various therapeutic segments, marketed under the Goldline brand, and is supported by an asset-light model that relies on external manufacturers. Currently, the IPO's grey market premium (GMP) is +25, suggesting a potential listing price of ₹68, which is 58.14% higher than the upper price band. The IPO aims to raise ₹11.61 crore, primarily to repay ₹8.35 crore in loans. The subscription breakdown shows robust interest, with retail investors subscribing at 264.47x and non-institutional investors at 365.75x. Cumulative Capital Pvt. Ltd is the lead manager for the offering, while Bigshare Services Pvt. Ltd is the registrar.